Articles tagged with: BHQ880
In a recent review article published in the journal Clinical Cancer Research, two myeloma experts from the Dana-Farber Cancer Institute, Dr. Nikhil Munshi and Dr. Kenneth Anderson, review the latest strategies in the treatment of multiple myeloma.
In their article, the experts discuss newer therapies that appear to be promising in clinical and preclinical studies.
According to the physicians, combination therapies that specifically target a patient’s genetic form of the disease will be required for long-term disease control and ultimately a cure.
Some Historical Perspective
In their review article, Drs. …
Today is the third day of the American Society of Hematology (ASH) 2012 annual meeting in Atlanta, and it is packed full with multiple myeloma-related presentations. Presentations started early in the morning and will continue through the afternoon.
Over the course of today, at least 11 different oral sessions, many of which are being held simultaneously, will include presentations about myeloma-related topics. The Beacon will summarize presentations from the four most relevant sessions in updates such as this one. This update, in particular, covers presentations from the first of those …
During the upcoming annual meeting of the American Society of Hematology (ASH), which will be held December 8 through 11 in Atlanta, results will be presented from clinical trials involving a number of potential new drugs under development for the treatment of multiple myeloma.
In particular, results for newer, lesser known agents that are in the early stages of clinical development will take center stage. These agents include ARRY-520 (filanesib), BHQ880, circularly permuted TRAIL, daratumumab, dinaciclib, lorvotuzumab mertansine, oprozomib, and tabalumab.
According to …
Earlier this year, an international group of myeloma experts published a review of ongoing research into new myeloma treatments. This review not only described a wide range of potential new myeloma treatments, but also included the experts’ thoughts on where research into new treatments should go in the future.
Given the recent new drug application for carfilzomib and the upcoming annual meeting of the American Society of Hematology — which undoubtedly will host discussions of many potential new myeloma treatments — it seems an appropriate time to go back to the …
Multiple myeloma is the most frequent cancer to involve the skeleton, with up to 80 percent of patients having bone disease. Although fewer patients appear to have bone involvement more recently, it is still a major source of both complications and death among patients with myeloma.
Bone disease is so severe in myeloma because the normal bone remodeling process is disrupted. In normal individuals, damaged bone is removed by bone-destroying cells, the osteoclasts, and then bone is replaced by bone-forming cells, the osteoblasts. In myeloma, the number and activity of …